China Infrastructure Construction Corp. (CHNC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Infrastructure Construction Corp. (CHNC) trades at $0.00 with AI Score 55/100 (Grade B). China Infrastructure Construction Corp. focuses on medical cannabis education and related services. Market cap: $5.04M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CHNC: CHNC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHNC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CHNC: the 6 perspectives are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →China Infrastructure Construction Corp. (CHNC) Healthcare & Pipeline Overview
China Infrastructure Construction Corp. provides medical cannabis education and related services, including clinical trials and sleep disorder treatments. Operating in the United States, Latin America, and globally through online platforms, the company distinguishes itself through its Pharmacology University and fertility/sleep center, amidst a competitive healthcare landscape.
What Is the Investment Thesis for CHNC?
China Infrastructure Construction Corp. presents a speculative investment opportunity within the medical cannabis education sector. The company's focus on online education and specialized services like clinical trials and sleep disorder treatments offers potential for growth, particularly as the medical cannabis market expands. With a market capitalization of $5.04M and a negative P/E ratio of -15.64, the company's financial performance requires careful monitoring. Key value drivers include the expansion of Pharmacology University's online education programs and the success of its fertility and sleep center. However, investors should be aware of the risks associated with OTC-traded stocks and the competitive landscape of the healthcare and cannabis industries. The company's beta of -0.22 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
CHNC Key Highlights
- Market capitalization of $5.04M indicates a micro-cap company with high growth potential but also significant risk.
- Gross margin of 66.6% suggests strong pricing power in its niche market of medical cannabis education and services.
- Negative P/E ratio of -15.64 reflects current unprofitability, requiring scrutiny of future earnings potential.
- Profit margin of -291.8% indicates substantial losses, highlighting the need for improved cost management and revenue generation.
- Beta of -0.22 suggests the stock is less volatile than the market, potentially offering some downside protection.
Who Are CHNC's Competitors?
CHNC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BCBCF The BC Bud Corporation | $0.04 | -3.31% | $5.98M | 56 |
| CLSH CLS Holdings USA, Inc. | $0.04 | +0.00% | $5.94M | 43 |
| FFLWF Fire & Flower Holdings Corp. | $0.12 | -44.37% | $5.42M | 41 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHNC's Key Strengths?
- Specialized expertise in medical cannabis education.
- Integrated service offerings including education, consulting, and clinical services.
- Online education platform with global reach.
- Established fertility and sleep center in Houston.
What Are CHNC's Weaknesses?
- Small market capitalization and limited financial resources.
- Negative profitability and high operating losses.
- Dependence on the evolving regulatory landscape of the medical cannabis industry.
- Limited brand recognition and market share.
What Could Drive CHNC Stock Higher?
- Expansion of online education programs through Pharmacology University.
- Increasing acceptance and legalization of medical cannabis in new markets.
- Potential partnerships with healthcare providers and cannabis dispensaries.
- Development of new clinical trial services focused on medical cannabis.
- Enhancement of fertility and sleep center services in Houston.
What Are the Key Risks for CHNC?
- Regulatory changes and legal restrictions on medical cannabis.
- Increasing competition from other educational platforms and healthcare providers.
- Small market capitalization and limited financial resources.
- Negative profitability and high operating losses.
- Economic downturns and reduced consumer spending.
What Are the Growth Opportunities for CHNC?
- Expansion of Online Education Programs: China Infrastructure Construction Corp. can capitalize on the growing demand for medical cannabis education by expanding its online programs through Pharmacology University. The global e-learning market is projected to reach $325 billion by 2025, providing a substantial opportunity for CHNC to increase its revenue and market share. This expansion can include new courses, certifications, and partnerships with healthcare institutions.
- Geographic Expansion into Latin America: The Latin American medical cannabis market is rapidly expanding, with countries like Colombia and Mexico legalizing medical cannabis. China Infrastructure Construction Corp. can leverage its existing presence in Latin America to establish new educational centers and partnerships, tapping into a high-growth market with increasing demand for medical cannabis education and services. This expansion can be achieved through strategic alliances and franchising opportunities.
- Development of Specialized Clinical Trial Services: CHNC can enhance its service offerings by developing specialized clinical trial services focused on medical cannabis applications. The global clinical trials market is projected to reach $68.9 billion by 2028, presenting a significant opportunity for CHNC to generate revenue through clinical research and development. This can involve partnerships with pharmaceutical companies and research institutions.
- Enhancement of Fertility and Sleep Center Services: The company can enhance its fertility and sleep center in Houston by offering advanced diagnostic and treatment options. The global sleep disorder market is projected to reach $112.7 billion by 2027, while the fertility services market is expected to reach $36 billion by 2026. CHNC can attract more patients by investing in state-of-the-art technology and expanding its range of services.
- Strategic Partnerships and Acquisitions: China Infrastructure Construction Corp. can pursue strategic partnerships and acquisitions to expand its market reach and service offerings. Collaborating with other companies in the healthcare and cannabis industries can provide access to new markets, technologies, and expertise. This can involve partnerships with cannabis dispensaries, healthcare providers, and educational institutions.
What Opportunities Does CHNC Have?
- Expansion into new geographic markets, particularly in Latin America.
- Development of new online education programs and certifications.
- Strategic partnerships with healthcare providers and cannabis dispensaries.
- Increased research and development in medical cannabis applications.
What Threats Does CHNC Face?
- Increasing competition from other educational platforms and healthcare providers.
- Changing regulations and legal restrictions on medical cannabis.
- Economic downturns and reduced consumer spending.
- Potential for negative publicity and reputational damage.
What Are CHNC's Competitive Advantages?
- Specialized Focus: Niche focus on medical cannabis education and related services.
- Proprietary Content: Unique educational content developed through Pharmacology University.
- Integrated Services: Combination of education, consulting, and clinical services.
- First-Mover Advantage: Early entrant in the medical cannabis education market.
What Does CHNC Do?
Founded in 2003 and headquartered in Houston, Texas, China Infrastructure Construction Corp. (CHNC) operates within the healthcare sector, focusing on the burgeoning medical cannabis industry. The company's core business revolves around providing educational systems centered on medical cannabis, extending its reach across the United States, Latin America, and worldwide via online education platforms. CHNC distinguishes itself by offering specialized services in therapeutic areas such as clinical trials and sleep disorders, including infertility treatments, through its fertility and sleep center located in Houston. CHNC's educational arm, Pharmacology University, delivers education, consulting, digital publishing, marketing, and franchising services related to medical cannabis. This multifaceted approach positions the company as a knowledge hub within the evolving cannabis market. While the company's market capitalization is modest, its comprehensive service offerings and educational focus provide a unique niche in the healthcare and cannabis sectors. The company's gross margin stands at 66.6%, indicating a strong potential for profitability despite a current negative profit margin of -291.8%.
What Products and Services Does CHNC Offer?
- Provides educational systems focused on medical cannabis.
- Offers online education programs through Pharmacology University.
- Provides services in clinical trials related to medical cannabis.
- Operates a fertility and sleep center in Houston, Texas.
- Offers treatments for sleep disorders, including resulting infertility.
- Provides education, consulting, digital publishing, and marketing services related to medical cannabis.
- Offers franchising opportunities related to medical cannabis education.
How Does CHNC Make Money?
- Generates revenue through online education programs and courses.
- Provides consulting and marketing services to businesses in the medical cannabis industry.
- Operates a fertility and sleep center, generating revenue through patient services.
- Offers franchising opportunities for Pharmacology University.
What Industry Does CHNC Operate In?
China Infrastructure Construction Corp. operates in the evolving medical cannabis industry, which is experiencing significant growth and regulatory changes. The market is characterized by increasing acceptance of medical cannabis for various therapeutic applications, driving demand for education and related services. CHNC competes with other educational platforms and healthcare providers in the sleep disorder and fertility treatment sectors. Companies like ACRDF (Acreage Holdings) and BCBCF (BevCanna Enterprises Inc.) represent competitors in the broader cannabis market, while CLSH (Clearside Biomedical Inc.) operates in the pharmaceutical space. The industry's growth is fueled by ongoing research, changing regulations, and increasing consumer awareness.
Who Are CHNC's Key Customers?
- Individuals seeking education on medical cannabis.
- Healthcare professionals interested in learning about medical cannabis applications.
- Businesses in the medical cannabis industry seeking consulting and marketing services.
- Patients seeking treatment for sleep disorders and infertility.
Company Profile
China Infrastructure Construction Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Dante Picazo. CHNC has traded publicly since 2009.
ROE 123%Key Financial Metrics
Return on equity for China Infrastructure Construction Corp. stands at 122.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -4.9%, the inverse of the P/E and a quick read on earnings relative to price.
CHNC Valuation & Market Position
With a $5.04M market cap, China Infrastructure Construction Corp. sits in the micro-cap segment of the market. Relative to its peer group, CHNC's quantitative score of 55/100 is roughly in line with the peer average of 55/100.
Quarterly Financial Performance: China Infrastructure Construction Corp.
Revenue for China Infrastructure Construction Corp. came in at $11K during Q1 2026, a 79.0% contraction versus the preceding quarter. The company recorded a net loss of $104K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CHNC averaged $0.00 in diluted EPS.
F-Score 4/9Financial Health
China Infrastructure Construction Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
CHNC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Social sentiment has shifted positively as community discussions highlight China's increasing infrastructure spending, which could benefit CHNC.
- Analysts have noted improvements in project approvals, which may lead to a stronger revenue stream for the company in the coming months.
- Positive media coverage around China's infrastructure initiatives has bolstered investor interest and sentiment towards CHNC.
Bear Case
- Concerns about regulatory changes in China create uncertainty, which may negatively impact investor confidence in infrastructure projects.
- Recent discussions in trading communities reflect skepticism about the company's ability to execute on large-scale projects amidst economic headwinds.
- There are worries about rising material costs affecting profit margins, leading to cautious sentiment among investors.
- The overall market perception remains cautious due to geopolitical tensions, which could hinder infrastructure investments and affect CHNC's performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11,205 | -$103,933 | $0.00 |
| Q4 2025 | $53,266 | -$116,966 | $0.00 |
| Q3 2025 | $24,200 | -$82,645 | -$0.01 |
| Q2 2025 | $34,956 | $20,394 | $0.03 |
Based on FMP financials and quantitative analysis
CHNC Latest News
No recent news available for CHNC.
CHNC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHNC.
Price Targets
Wall Street price target analysis for CHNC.
CHNC MoonshotScore
What does this score mean?
The MoonshotScore rates CHNC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dante Picazo
Managing
Dante Picazo is the managing individual at China Infrastructure Construction Corp. His role involves overseeing the company's operations, strategy, and growth initiatives. Given the company's small size of 2 employees, Mr. Picazo likely has a hands-on approach, managing various aspects of the business from educational program development to clinical service oversight. His leadership is crucial in navigating the evolving medical cannabis industry and driving the company's strategic direction.
Track Record: Due to limited information available, Dante Picazo's specific achievements and strategic decisions at China Infrastructure Construction Corp. are unknown. Assessing his track record would require further insights into the company's performance and key milestones under his leadership. The company's current financial status, including its negative profitability, suggests potential challenges in his tenure.
CHNC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Infrastructure Construction Corp. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports, leading to increased risks for investors. Investing in OTC Other stocks requires thorough due diligence and an understanding of the potential risks involved compared to stocks listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: Lack of regular financial reporting increases information asymmetry and risk.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Susceptibility to significant price swings due to limited trading activity.
- Potential for Manipulation: Increased risk of market manipulation due to less regulatory oversight.
- Going Concern Risk: Higher risk of business failure compared to companies on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue streams and profitability.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Business: Founded in 2003, indicating some operational history.
- Specialized Services: Focus on medical cannabis education and related services.
- Physical Location: Operates a fertility and sleep center in Houston, Texas.
- Online Presence: Offers online education programs through Pharmacology University.
Common Questions About CHNC (Healthcare)
What does China Infrastructure Construction Corp. do?
China Infrastructure Construction Corp. operates primarily in the medical cannabis education and services sector. Through its Pharmacology University, the company provides online education programs focused on medical cannabis applications. Additionally, it offers consulting and marketing services to businesses within the medical cannabis industry. The company also operates a fertility and sleep center in Houston, Texas, providing treatments for sleep disorders and infertility, integrating clinical services with its educational offerings. This multifaceted approach positions CHNC as a unique player in the evolving healthcare and cannabis landscape.
What are the key growth opportunities for CHNC in healthcare?
China Infrastructure Construction Corp. can capitalize on several growth opportunities within the healthcare sector. Expanding its online education programs to reach a broader audience, particularly in emerging markets with increasing acceptance of medical cannabis, presents a significant avenue for growth. Developing specialized clinical trial services focused on medical cannabis applications can also generate revenue through research and development partnerships. Furthermore, enhancing the services offered at its fertility and sleep center, including advanced diagnostic and treatment options, can attract more patients and increase revenue streams. Strategic partnerships with healthcare providers and cannabis dispensaries can further expand its market reach.
What are the main risks for CHNC?
China Infrastructure Construction Corp. faces several risks inherent to its business model and the evolving medical cannabis industry. Regulatory changes and legal restrictions on medical cannabis pose a significant threat, as changes in legislation can impact the company's operations and market access. Increasing competition from other educational platforms and healthcare providers can erode its market share and profitability. The company's small market capitalization and limited financial resources also present challenges, potentially hindering its ability to invest in growth initiatives and compete effectively. Furthermore, economic downturns and reduced consumer spending can impact demand for its services.
What are the key factors to evaluate for CHNC?
China Infrastructure Construction Corp. (CHNC) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does CHNC data refresh on this page?
CHNC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CHNC's recent stock price performance?
China Infrastructure Construction Corp. (CHNC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in medical cannabis education. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHNC overvalued or undervalued right now?
Valuing China Infrastructure Construction Corp. (CHNC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CHNC?
Before investing in China Infrastructure Construction Corp. (CHNC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and disclosure status.
- AI analysis is pending and may provide further insights.